{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:16:29Z","timestamp":1790212589540,"version":"4.1.0"},"reference-count":44,"publisher":"BMJ","issue":"9","funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,6,12]]},"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the changes in prescribing of oral anticoagulant (AC) and antiplatelet (AP) agents in patients with non-valvular atrial fibrillation (NVAF) in the UK and to identify the characteristics associated with deviation from guideline-based recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Five cross-sectional analyses in a large retrospective population-based cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>General practices contributing data to the UK Clinical Practice Research Datalink.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      The study included patients with a diagnosis of NVAF and eligible for anticoagulation (CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VASc score \u22652) on 1 April of 2012, 2013, 2014, 2015 and 1st January 2016.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proportion of patients being treated with AC increased at each index date, showing an absolute rise of 16.7% over the study period. At the same time, the proportion of patients treated with an AP alone was reduced by half, showing an absolute decrease of 16.8%. The proportion of patients not receiving any antithrombotic (AT) treatment remained the same across the study period. A number of predictors were identified for AP alone or no treatment compared with AC treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Major improvements in the AT management of patients with NVAF for stroke prevention in the UK were observed between April 2012 and January 2016. Despite this, nearly 20% of at-risk patients still received AP alone and over 15% were on no AT agents in January 2016.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-015363","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T20:10:22Z","timestamp":1506456622000},"page":"e015363","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD"],"prefix":"10.1136","volume":"7","author":[{"given":"Laure","family":"Lacoin","sequence":"first","affiliation":[{"name":"UK Medical Department, Bristol-Myers Squibb, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lumley","sequence":"additional","affiliation":[{"name":"Medical Department, Pfizer, Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essra","family":"Ridha","sequence":"additional","affiliation":[{"name":"UK Medical Department, Bristol-Myers Squibb, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pereira","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Evidera, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"McDonald","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Evidera, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeram","family":"Ramagopalan","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Evidera, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinira","family":"Lef\u00e8vre","sequence":"additional","affiliation":[{"name":"Center of Observational Research and Data Sciences, Business Insights and Analytics, Bristol-Myers Squibb, Rueil Malmaison, France"},{"name":"Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Rueil Malmaison, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Evans","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Rueil Malmaison, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-2947","authenticated-orcid":false,"given":"Julian P","family":"Halcox","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Swansea University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"2025121602365841000_7.9.e015363.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.18.2370"},{"key":"2025121602365841000_7.9.e015363.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005119"},{"key":"2025121602365841000_7.9.e015363.3","unstructured":"England PH . Atrial fibrillation prevalence estimates in England: application of recent population estimates of AF in Sweden. 2015;2015 http:\/\/www.yhpho.org.uk\/\/resource\/view.aspx?RID=207902"},{"key":"2025121602365841000_7.9.e015363.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm358"},{"key":"2025121602365841000_7.9.e015363.5","unstructured":"Royal College of Physicians. Sentinel Stroke National Audit Programme (SSNAP). Clinical audit April - June 2015 report prepared by Royal College of Physicians, Clinical Effectiveness and Evaluation Unit on behalf of the Intercollegiate Stroke Working Party. 2015."},{"key":"2025121602365841000_7.9.e015363.6","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.27.10.1760"},{"key":"2025121602365841000_7.9.e015363.7","doi-asserted-by":"publisher","DOI":"10.1136\/heart.86.3.284"},{"key":"2025121602365841000_7.9.e015363.8","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.069492"},{"key":"2025121602365841000_7.9.e015363.9","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp12X656856"},{"key":"2025121602365841000_7.9.e015363.10","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123 645","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"2025121602365841000_7.9.e015363.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl015"},{"key":"2025121602365841000_7.9.e015363.12","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2011-300901"},{"key":"2025121602365841000_7.9.e015363.13","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-303472"},{"key":"2025121602365841000_7.9.e015363.14","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eus305"},{"key":"2025121602365841000_7.9.e015363.15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"2025121602365841000_7.9.e015363.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04302.x"},{"key":"2025121602365841000_7.9.e015363.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.111.966713"},{"key":"2025121602365841000_7.9.e015363.18","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0175"},{"key":"2025121602365841000_7.9.e015363.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04085.x"},{"key":"2025121602365841000_7.9.e015363.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.10.096"},{"key":"2025121602365841000_7.9.e015363.21","unstructured":"Royal College of Physicans. Sentinel Stroke National Audit Programme (SSNAP). Clinical audit first pilot public report 2013."},{"key":"2025121602365841000_7.9.e015363.22","unstructured":"National Clinical Guideline Centre. Atrial fibrillation: the management of atrial fibrillation. Clinical guideline: methods, evidence and recommendations [NICE CG180]. 2014."},{"key":"2025121602365841000_7.9.e015363.23","unstructured":"NICE Implementation Collaborative. Consensus supporting local implementation of NICE guidance on use of the novel (non-Vitamin K antagonist) oral anticoagulants in non-valvular atrial fibrillation. 2014."},{"key":"2025121602365841000_7.9.e015363.24","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025121602365841000_7.9.e015363.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003839","article-title":"Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes","volume":"4","author":"Gallagher","year":"2014","journal-title":"BMJ Open"},{"key":"2025121602365841000_7.9.e015363.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.acap.2013.08.002"},{"key":"2025121602365841000_7.9.e015363.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw233"},{"key":"2025121602365841000_7.9.e015363.28","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjmed.2015.07.013","article-title":"Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II","volume":"128 1313","author":"Huisman","year":"2015","journal-title":"Am J Med"},{"key":"2025121602365841000_7.9.e015363.29","doi-asserted-by":"crossref","unstructured":"Camm AJ , Accetta G , Ambrosio G , et al . Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart 2017;103.doi:10.1136\/heartjnl-2016-309832","DOI":"10.1136\/heartjnl-2016-309832"},{"key":"2025121602365841000_7.9.e015363.30","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"2016","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2025121602365841000_7.9.e015363.31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl146"},{"key":"2025121602365841000_7.9.e015363.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.06.077"},{"key":"2025121602365841000_7.9.e015363.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03059.x"},{"key":"2025121602365841000_7.9.e015363.34","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1329"},{"key":"2025121602365841000_7.9.e015363.35","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000173398.99163.9e"},{"key":"2025121602365841000_7.9.e015363.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61233-1"},{"key":"2025121602365841000_7.9.e015363.37","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afl129"},{"key":"2025121602365841000_7.9.e015363.38","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.526988"},{"key":"2025121602365841000_7.9.e015363.39","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K498"},{"key":"2025121602365841000_7.9.e015363.40","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302843"},{"key":"2025121602365841000_7.9.e015363.41","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.10.946"},{"key":"2025121602365841000_7.9.e015363.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01236-6"},{"key":"2025121602365841000_7.9.e015363.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06379.x"},{"key":"2025121602365841000_7.9.e015363.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-015363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:37:03Z","timestamp":1765881423000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-015363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,25]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1136\/bmjopen-2016-015363"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-015363","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}